| Date | Title | Description |
| 06.07.2024 | Endogenex: $88 Million Raised To Improve Outcomes In Individuals With Type 2 Diabetes | Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes, announced it closed an oversubscribed Series C financing totaling $88 million.
The new funding round will be used to com... |
| 23.06.2021 | RapidPulse Launches with $15M for Ischemic Stroke Therapy | – RapidPulse, Inc., a Miami-based medical device company developing a novel aspiration system to treat ischemic stroke, today announced it has raised $15M in Series A funding led by Santé Ventures who was joined by Epidarex Capital, Hattera... |
| 15.04.2019 | Term Sheet — Monday, April 15 | FAILING THE QUIZ
The latest drama out of startup-land? Of all the things, it’s a power struggle of who will lead live trivia game show startup HQ Trivia.
Paid Content What you need to know about growing cyberattacks From ExtraHop
HQ Trivia ... |
| 15.04.2019 | Hatteras Raises $94M For Sixth Fund | DURHAM, N.C., April 15, 2019 (GLOBE NEWSWIRE) — Hatteras Venture Partners announced today the first closing of Hatteras Venture Partners VI, LP (HVP VI), with $94 million in deployable capital toward an ultimate target fund size of $200 mil... |
| 15.04.2019 | Hatteras Raises $94M For Sixth Fund | DURHAM, N.C., April 15, 2019 (GLOBE NEWSWIRE) — Hatteras Venture Partners announced today the first closing of Hatteras Venture Partners VI, LP (HVP VI), with $94 million in deployable capital toward an ultimate target fund size of $200 mil... |
| 03.01.2019 | Hatteras Venture Partners-backed StrideBio Appoints Sapan Shah as CEO | StrideBio, Inc, a leading developer of novel adeno-associated viral (AAV) based gene therapies, announced today that the Board of Directors has appointed Sapan Shah, Ph.D. as Chief Executive Officer and a member of the company’s board.
Dr S... |
| 03.01.2019 | Hatteras Venture Partners-backed StrideBio Appoints Sapan Shah as CEO | StrideBio, Inc, a leading developer of novel adeno-associated viral (AAV) based gene therapies, announced today that the Board of Directors has appointed Sapan Shah, Ph.D. as Chief Executive Officer and a member of the company’s board.
Dr S... |
| 14.06.2018 | StrideBio Raises $15.7M Series A | StrideBio, Inc, a US-based company developing novel AAV vectors for in vivo gene therapies announced today that it had closed an oversubscribed Series A Financing Round of $15.7 million. The financing was led by Hatteras Venture Partners. C... |
| 23.04.2018 | 8VC has closed its second early-stage fund, seemingly with an eye on logistics and biotech | 8VC, the early-stage, San Francisco-based venture firm founded in 2015 by serial entrepreneur Joe Lonsdale and four other general partners, has closed it second early-stage venture fund with $640 million in commitments, says one of its inve... |
| 19.01.2018 | NurseGrid raises $5.7M for scheduling and staffing tech platform for nurses | NurseGrid’s platform helps hospitals and other care providers with scheduling and staffing their nurse employees. (NurseGrid Photo)
Operating a hospital is no easy task, and at the moment, finding technology to help in that task is also a c... |
| 22.09.2017 | Hatteras Venture Partners Names Sir Andrew Witty as Venture Partner | Hatteras Venture Partners, a venture capital firm based in Research Triangle Park, N.C., named Sir Andrew Witty as a Venture Partner.
Mr. Witty will primarily focus on the strategic positioning of Hatteras and its portfolio companies in the... |
| 20.09.2017 | Term Sheet — Wednesday, September 20 | THE ROBOTS ARE COMING
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
It is so massive—its investors range from a Saudi sovereign wealth fund to Apple—that small stakes are impossible ... |
| 19.09.2017 | Ex-GlaxoSmithKline CEO Witty joins Hatteras as venture partner | Sir Andrew Witty has joined Hatteras Venture Partners. The former GlaxoSmithKline CEO is taking up a venture partner position at the VC shop, setting him up to offer advice on the positioning of its portfolio companies.
Witty stepped down a... |
| 19.09.2017 | Ex-GlaxoSmithKline CEO Witty joins Hatteras as venture partner
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Sir Andrew Witty has joined Hatteras Venture Partners. The former GlaxoSmithKline CEO is taking up a venture partner position at the VC shop, setting him up to offer advice on the positioning of its portfolio companies.
Sponsored by Agilent... |
| 09.03.2017 | Agtech Funding (& Exit) Sheet: $84m Raised in 2 Weeks (+$400m Instacart Series D), Origin Acquires AgSpace | AgSpace, a UK ag big data startup, has been acquired by Origin Enterprises, the ag retailer and agronomy company for £11.4 million ($13.9m). A further payment of £4.8m ($5.9m) will be made if the company reaches its profit targets. AgSpace ... |
| 02.03.2017 | AgTech Accelerator Launches First Startup Bringing Gates Foundation to Boragen $10m Series A | AgTech Accelerator, the venture development organization, has launched its first startup, Boragen, leading a $10 million Series A for the ag biotech startup.
AgTech Accelerator invested $3 million of its current $20 million capital pool and... |
| 28.02.2017 | Hatteras Venture Partners Launches the Venture Capital Multiplier Fund | Hatteras Venture Partners, a venture capital firm based in Research Triangle Park, NC, has announced the launch of the Venture Capital Multiplier Fund.
Selected by the State of North Carolina, Hatteras Venture Partners will be the manager o... |
| 06.02.2017 | Artizan Biosciences Raises Founding Equity Round of Undisclosed Amount | Artizan Biosciences, Inc., a Durham, NC-based biotechnology company, raised a founding equity round of undisclosed amount.
Malin Corporation plc., an Irish incorporated public based and globally operating life sciences company, acquired a 3... |
| 06.01.2017 | Term Sheet — Friday, January 6 | CES, CMO, IPO, CAIO
Unicorn Watch: Yesterday I interviewed Xiaomi CFO Shou Zi Chew, formerly a partner at DST Global. Xiaomi, valued at $45 billion, is at CES hoping to deliver on its promise of a broad tech ecosystem offering a variety of ... |
| 05.01.2017 | Hatteras Venture Partners Closes Fund V, at over $150M | Durham, N.C.-based venture capital firm Hatteras Venture Partners closed its fifth fund with over $150m in total capital.
Hatteras Venture Partners V (HVP V) will continue the firm’s strategy of building biopharmaceutical, medical device, d... |
| 23.03.2016 | Daily funding roundup - March 23, 2016 | DoorDash bagged $127M funding; ezbuy received $20M investment; Betterworks raised $20M
The History Project, a company that seeks, to be a modern reinvention of the time capsule, raised an undisclosed amount of funding from The Associated Pr... |
| 23.03.2016 | Bivarus raises $2M to add staff for patient-centered analytics, roll out data visualization engine | In response to customer demand, it has worked on services in the past 12 months to give them more relevant, reliable, targeted information based on patient generated data. By the end of June, it anticipates launching a visualization engine ... |
| 03.03.2016 | Carolina Research Ventures Selectes Hatteras Venture Partners as Manager of Fund | Carolina Research Ventures, LLC, selected Research Triangle Park, NC-based venture capital firm Hatteras Venture Partners as the manager of its investment fund.
CRV is an early stage venture investment fund created to support companies sour... |
| 29.10.2015 | Daily funding roundup - October 29, 2015 | Brandwatch completed $33M funding; Qvella raised $20M; Gobble landed $10.75M
Mangatar, a Milan, and Salerno, Italy-based social and mobile gaming startup, raised €1.1 million ($1.2 million) in funding. The funds were raised via Fi.R.A. (Fin... |
| 01.09.2015 | Daily funding roundup - September 1, 2015 | IDG nabbed $120M; Cequr raised $100M; Cloud Apps Capital Partners bagged $53.7M
Cloud business software companies are currently in a strange position when it comes to venture capital. They require more capital and board support than the see... |
| 01.09.2015 | Medfusion Raises $3M in Funding | Medfusion, Inc., a Cary, N.C.-based patient engagement platform dedicated to facilitating the relationship between doctors and patients, raised $3m in funding.
Backers included Bull City Venture Partners and Hatteras Venture Partners. As pa... |
| 26.08.2015 | Hatteras Venture Partners Holds First Close of Venture Capital Fund at more than $90M | Research Triangle Park, NC-based venture capital firm Hatteras Venture Partners held the first closing of its Fund V at more than $90m.
Hatteras Venture Partners V (HVP V), which has a final target of $150m, will focus on investing in human... |
| 25.08.2015 | Morning Read: Hatteras Venture Partners raises $90M for fifth fund, BioMarin in $570M breast cancer drug deal | PAYERS-PROVIDERS
A series of pilot programs in Ventura and Los Angeles counties are using some paramedics for non emergency, preventive care for areas like congestive heart failure and tuberculosis. The hope is that preventive care will sav... |
| 26.06.2015 | Wildflower Health raises $5M to expand mobile maternity apps for health plans | Wildflower also agreed to a strategic partnership with Everyday Health. It runs the “What to Expect” digital franchise that reaches about 75 percent of pregnant women in the United States. The idea is to extend Wildflower’s services to heal... |
| 06.02.2015 | ORIG3N Raises $3.1M in Funding | ORIG3N, a Boston, MA-based biotechnology company, raised $3.1m in funding.
Backers included Hatteras Venture Partners, Harris & Harris Group, KTB and Mountain Group Capital.
The company intends to use the funds to expand its Life Capsul... |
| 19.08.2014 | Clinverse raises $9.1M to take complexities out of clinical trial payments | In response to emailed questions, a spokesman for the company said automating the financial services side of clinical trials is a quickly evolving, relatively, untapped growing market with plenty of room for the companies developing these s... |
| 22.07.2014 | MoneyTree Reports $121M in MI Venture Deals Last Quarter | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Venture Capital investors had a very active second quarter of 2014, according to the latest MoneyTree report. VCs invested almost $13 billion in 1,114 U.S. startups during the... |
| 18.12.2013 | Harvard-Spun Curoverse Raises $1.5M to Build Biomedical Big Data Platform | Biomedical big data is receiving a new platform. Curoverse announced Wednesday the Harvard-spun startup has raised $1.5 million to accelerate the development of Arvados, its open-source computational storage platform currently being used at... |
| 16.10.2013 | G1 Therapeutics Raises $12.5M in Series A Financing | G1 Therapeutics, Inc., Chapel Hill, NC-based pharmaceutical company that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications, raised $12.5M in Series A financing.
The round... |
| 17.06.2013 | Applying neuromodulation to acute heart failure nets NC device startup a $13M series A | NeuroTronik is creating a device that cardiologists would use to stimulate a patient’s heart so that it could pump blood more effectively. This kind of treatment has the potential to shorten hospital stays and reduce the need for patients t... |
| 01.05.2013 | G1 Therapeutics developing treatment to protect soldiers, chemo patients from radiation damage | The team is working on two formulations of the same molecule. The lead formulation is in intravenous form that could be added to existing chemo treatments.
“This allows us to exquisitely tune in the dose and to turn it on or turn it off,” C... |
| 18.02.2013 | Ophthalmology startup uses microneedles for targeted delivery of drugs for retinal diseases | According to a statement from the company, the funding came from Santen Inc., the California-based subsidiary of Santen Pharmaceuticals Co., Ltd in Japan, and other investors including Mountain Group Capital, Hatteras Venture Partners, Geor... |
| 07.01.2013 | Hatteras Venture Partners Closes Fourth Fund at $125M | Durham, NC-based venture capital firm Hatteras Venture Partners closed its fourth fund at $125m.
As a part of the final closing, Hatteras Venture Partners IV (HVP IV) established a subsidiary fund, HVP IV SBIC, that is a licensee of the US ... |
| 07.01.2013 | $125M early stage fund seeks to invest in health startups in N.C. and southeastern U.S. | The HVP IV fund also established a HVP IV SBIC, which is the first licensee of the U.S. Small Business Administration’s (SBA) newly established Early Stage SBIC Program.
An earlier, initial closing of the HPV IV fund in 2011 led to the esta... |
| 17.12.2012 | Cancer therapeutic that causes “executioner” protein to kill cancer cells raises $5M | The latest financing follows a $6 million fresh capital raise last year. In October 2010, it raised $32 million in a Series C round.
Among the company’s institutional investors are Clarus Ventures, HealthCare Ventures, Quaker Partners, Novi... |
| 21.08.2012 | Type 2 diabetes drug with goal of 24/7 glycemic control begins Phase 2b trial | The biotechnology firm raised $48.4 million earlier this year in its third tranche for its series B financing round led by New Enterprise Associates with participation by Hatteras Venture Partners, Johnson & Johnson Development Corp., A... |
| 07.05.2012 | Clinverse Closes $3.8M Series B Funding Round | Clinverse, Inc., a Raleigh, NC-based SaaS ecommerce platform provider for clinical trials, has closed a $3.8m Series B round of funding.
The round was led by Hatteras Venture Partners, with participation from Vital Financial.
Led by CEO Tim... |
| 07.05.2012 | Run a clinical trial, get paid faster — Clinverse raises $3.8M for software | Clinical investigators are paid according to contracts that are all separately negotiated depending on the experiment. Payment is determined by matching whether the clinical trial site met the terms set out in the contract language — a proc... |
| 28.02.2012 | Peripheral artery disease device company raises $2.5 million | Angioplasty is a procedure that uses balloons to widen narrowed or obstructed blood vessels. In the case of peripheral artery disease, the blood vessels can be located in the abdomen, legs or kidneys. Peripheral artery disease affects 8 mil... |
| 06.01.2012 | Clearside Biomedical Launches with $4M Series A Venture Financing | Clearside Biomedical, an Atlanta, GA-based ophthalmic startup specializing in the research, development and commercialization of therapeutic products through a proprietary ocular microinjection platform that targets the individual compartme... |
| 05.01.2012 | Clearside raises $4M for targeted drug delivery system and new eye drug | Clearside will direct the investment toward development of its novel microinjection drug delivery platform. The company’s microneedle technology allows for delivery of drugs and proteins to the retina and other hard to access parts of the e... |
| 03.11.2011 | N.C. ‘Accelerator’ to invest $35M in early-stage life science companies | “The Accelerator is designed not only to provide capital but also to create partnerships and leverage additional resources to support some of the most enterprising thinkers and businesses in the state,” Cowell said.
The Accelerator is part ... |
| 10.10.2011 | Antibacterial technology from Novan lands $6M in new capital | In addition to equity financing from investors, Novan has grants from the National Institutes of Health to study the technology in applications such as antimicrobial catheter coatings intended to prevent hospital acquired infections. Novan ... |
| 20.09.2011 | Cancer diagnostics firm GeneCentric raises $250,000 | Perou and Hayes are already working together on genomic cancer research. The two are leading a team of UNC researchers supported by a Cancer Genome Atlas Grant. In August, UNC was named as one of 12 research centers participating in the eff... |
| 17.08.2011 | Hatteras Venture Partners Holds First Close Fund IV at $74M | Hatteras Venture Partners, a Durham, NC-based venture capital firm , with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine, has held the first close of Hatteras Venture Partners IV at ... |
| 17.08.2011 | ‘Hatteras Discovery’ launches; up to $25M set for life sciences seed funding | With Hatteras’s first three funds, the firm has more than $120 million under management. Hatteras is still investing from its third fund, an $83 million early stage fund that invests in “breakthrough discoveries that impact human medicine.”... |
| 03.12.2010 | Diabetes, cardiovascular drug developer PhaseBio adds $15M | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R... |
| 07.06.2007 | Viamet raises $4M for metalloenzyme-targeting drugs | Research Triangle Park, N.C.-based Viamet raised $4 million in a first round of funding. The round was co-led by Hatteras Venture Partners and Intersouth Partners.
Viamet is developing drugs that target metalloenzymes — a diverse group of c... |
| - | Bivarus raises $2M to add staff for patient-centered analytics, roll out data visualization engine | Bivarus, a health IT company that analyzes patient-generated data to help healthcare providers figure out what they need to do to improve, has raised a $2 million funding round. In a phone interview, CEO Dave Levin said the funds will suppo... |
| - | Diabetes, cardiovascular drug developer PhaseBio adds $15M | The Philadelphia-area biopharma company PhaseBio Pharmaceuticals has received the final $15 million of a $25 million investment to fund further testing of its lead drug, which focuses on hyperglycemia related to Type 2 diabetes.
The company... |
| - | Ophthalmology startup uses microneedles for targeted delivery of drugs for retinal diseases | A one-year-old company using drug delivery to improve ophthalmic drugs is raising fresh capital to support trials of its microinjection platform.
Clearside Biomedical has raised $7.9 million and could continue raising up to $8.5 million, ac... |
| - | Antibacterial technology from Novan lands $6M in new capital | Nanotechnology company Novan has raised $6 million in financing as the startup continues development of its nitric oxide technology into a bacteria-fighting tool.
Securities filings show that Durham, North Carolina-based Novan’s latest roun... |
| - | Type 2 diabetes drug with goal of 24/7 glycemic control begins Phase 2b trial | A biotechnology company developing a long-acting drug for hyperglycemia associated with type 2 diabetes has initiated a multisite Phase 2b trial, according to a company statement.
PhaseBio Pharmaceuticals‘ lead drug Glymera is a recombinant... |
| - | Wildflower Health raises $5M to expand mobile maternity apps for health plans | Wildflower Health, a digital health startup behind mobile maternity program Due Date Plus, raised $5 million to support a strategic expansion, according to a company statement. The funding will also go towards product development.
Since its... |
| - | ‘Hatteras Discovery’ launches; up to $25M set for life sciences seed funding | Hatteras Venture Partners‘s fourth venture fund is closing in on its $125 million target and the venture capital firm has now formally launched the seed-stage portion of the fund, which will invest in seed-stage opportunities in medicine an... |
| - | G1 Therapeutics developing treatment to protect soldiers, chemo patients from radiation damage | After the Boston Marathon bombing, it’s easy to understand why the government is giving G1 Therapeutics millions of dollars to develop a pill that protects against radiation exposure.
If the pressure-cooker bomb had been a dirty bomb instea... |
| - | Cancer diagnostics firm GeneCentric raises $250,000 | Cancer diagnostics startup GeneCentric Diagnostics, led by former LabCorp (NYSE:LH) executive Dr. Myla Lai-Goldman, has raised $250,000, securities filings show.
Besides Lai-Goldman, GeneCentric’s CEO, the filing lists only Dr. Neil Hayes, ... |
| - | Clearside raises $4M for targeted drug delivery system and new eye drug | Ophthalmic startup Clearside Biomedical has launched with a $4 million initial round of investment for the company to continue R&D on its lead drug candidate and a novel drug delivery system that could administer that drug in hard to ac... |
| - | Clinverse raises $9.1M to take complexities out of clinical trial payments | If you had to do an infographic following the trajectory of clinical trial payments between the pharmaceutical companies that sponsor global clinical trials and the principal investigators who run them, it would resemble something like tang... |
| - | Cancer therapeutic that causes “executioner” protein to kill cancer cells raises $5M | A company with a small molecule cancer treatment to combat solid tumor cancers as well as hematological malignancies has raised $5 million in a combination of debt, options and warrants, according to a Form D filing with the Securities and ... |
| - | N.C. ‘Accelerator’ to invest $35M in early-stage life science companies | Early-stage life science companies have long grumbled about the ability to secure financing and those grumbles have only grown louder given the market conditions that have dried up many financing options.
The state of North Carolina will no... |
| - | Run a clinical trial, get paid faster — Clinverse raises $3.8M for software | The clinical trials process is becoming more of an electronic endeavor as the proliferation of data sparks new software to efficiently manage it. But one aspect of these studies has remained manual and slow: payment to the doctors who run t... |
| - | Morning Read: Hatteras Venture Partners raises $90M for fifth fund, BioMarin in $570M breast cancer drug deal | TOP STORIES
Hatteras Venture Partners has raised $90 million as part of its first close for its fifth venture fund. According to its website the company hopes to raise $150 million for the fund — which would be its largest to date. It will ... |
| - | Applying neuromodulation to acute heart failure nets NC device startup a $13M series A | Neurostimulation devices that send mild electrical pulses to target nerves are arguably the fastest-growing segment of the medical devices sector. They’re primarily being commercialized in neurology and urology but are apparently showing pr... |
| - | $125M early stage fund seeks to invest in health startups in N.C. and southeastern U.S. | Hatteras Venture Partners announced Monday that the company has closed its fourth fund totaling $125 million.
The Durham, North Carolina-based venture capital firm invests in device, diagnostic, biopharma, health IT and human-health related... |
| - | Peripheral artery disease device company raises $2.5 million | A medical device company developing an implant for optimized angioplasty to treat peripheral artery disease has raised $2.5 million since September.
The device is a permanent implant that would tack up the plaque blocking or restricting blo... |
